[ad_1]
A healthcare professional in Alaska, USA, suffered a severe allergic reaction after receiving the Covid-19 vaccine from Pfizer-BioNTech and is now hospitalized, but stable. “She is healthy and well,” revealed a person at Bertlett Hospital in Juneau.
The New York Times revealed Wednesday that the person received the vaccine on Tuesday and that Pfizer confirmed it was working with local authorities to investigate the incident. According to the American newspaper report, the middle-aged woman had no allergies in the past, but had an anaphylactic reaction ten minutes after receiving the vaccine. She felt short of breath and skin irritation.
According to Lindy Jones, head of the hospital’s emergency service, the health professional could be discharged later this Wednesday and remains excited to have received the vaccine.
Two health professionals in Britain had similar allergic reactions, prompting the British government to alert the public to avoid the vaccine if there was a history of severe allergies. The US regulator also issued an emergency approval warning of known allergies to the vaccine ingredients.
“We do not yet have all the details of the Alaska report on a possible severe allergic reaction, but we are actively working with local health authorities to evaluate it,” said a Pfizer spokesman. “We will closely monitor all reports suggesting serious allergic reactions after vaccination and update the label language if necessary.”
In the vaccine indications, it is mentioned that it is possible to have a “rare severe anaphylactic reaction”, so it is necessary that medical treatment be available at the time of inoculation.
Volunteers from Pfizer’s clinical trial of 44,000 people were excluded if they had a history of allergic reactions to Covid-19 vaccines or vaccine components.
Overall, the trial found no serious safety concerns, but regulators and the company continue to monitor for adverse events after vaccination. The United States is vaccinating about three million people this week and expects to reach a total of 20 million people this month if another vaccine, developed by Moderna, is approved.
[ad_2]
